43 related articles for article (PubMed ID: 32216970)
1. [STRN::ALK fusion renal cell carcinoma with lung metastasis: report of a case].
Xian J; Yin XX; Wang DH; Zhang MX; Zheng LM; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):631-633. PubMed ID: 38825915
[TBL] [Abstract][Full Text] [Related]
2. Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
Soumerai JD; Rosenthal A; Harkins S; Duffy J; Mecca C; Wang Y; Grewal RK; El-Jawahri AR; Liu H; Menard C; Dogan A; Yang L; Rimsza LM; Bantilan K; Martin H; Lei M; Mohr S; Kurilovich A; Kudryashova O; Postovalova E; Nardi V; Abramson JS; Chiarle R; Zelenetz AD; Louissaint A
Blood; 2022 Oct; 140(16):1822-1826. PubMed ID: 35802834
[No Abstract] [Full Text] [Related]
3. Spontaneous Partial Regression of Fetal Lung Interstitial Tumor With
Tan-Garcia A; Lee YT; Kuick CH; Soh SY; Chang KT; Merchant K
Pediatr Dev Pathol; 2024; 27(2):187-192. PubMed ID: 37818649
[TBL] [Abstract][Full Text] [Related]
4. Responses to
Wang R; Qin J; Fan Y; Li Z; Chen C; Su W
Onco Targets Ther; 2020; 13():4183-4187. PubMed ID: 32523354
[TBL] [Abstract][Full Text] [Related]
5. Dynamic cfDNA Analysis by NGS in
Ma L; Li H; Wang D; Hu Y; Yu M; Zhang Q; Qin N; Zhang X; Li X; Zhang H; Wu Y; Lv J; Yang X; Yu R; Zhang S; Wang J
Front Oncol; 2021; 11():643199. PubMed ID: 33842353
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of iruplinalkib (WX‑0593) on non‑small cell lung cancer with
Zhang Q; Lv J; Li X; Zhang H; Zhu C; Wang M; Si M; Hu Y; Zhang S
Exp Ther Med; 2024 Feb; 27(2):53. PubMed ID: 38234623
[TBL] [Abstract][Full Text] [Related]
7. BCL6-SPECC1L: A Novel Fusion Gene in Nasopharyngeal Carcinoma.
Fang SG; Xia TL; Fu JC; Li T; Zhong Q; Han F
Technol Cancer Res Treat; 2022; 21():15330338221139981. PubMed ID: 36412101
[No Abstract] [Full Text] [Related]
8. Cytospin-A Regulates Colorectal Cancer Cell Division and Migration by Modulating Stability of Microtubules and Actin Filaments.
Fan F; Roszik J; Xia L; Ghosh S; Wang R; Ye X; Hawke D; Ellis LM; Bhattacharya R
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454887
[TBL] [Abstract][Full Text] [Related]
9. Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.
Zhai X; Wu Q; Pu D; Yin L; Wang W; Zhu D; Xu F
Front Oncol; 2021; 11():782682. PubMed ID: 35070986
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report.
Wu X; Zhou H; He Z; Zhang Z; Feng W; Zhao J; Chen H; Wang S; Wang W; Wang Q
Transl Lung Cancer Res; 2020 Dec; 9(6):2494-2499. PubMed ID: 33489809
[TBL] [Abstract][Full Text] [Related]
11. A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib.
Zhang J; Zou C; Zhou C; Luo Y; He Q; Sun Y; Zhou J; Ke Z
J Thorac Oncol; 2020 Jun; 15(6):1073-1077. PubMed ID: 32217130
[No Abstract] [Full Text] [Related]
12. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
13. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
Singhi EK; Horn L
Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
[TBL] [Abstract][Full Text] [Related]
14. SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer.
Ma L; Zhang Q; Dong Y; Li H; Wang J
Lung Cancer; 2020 May; 143():97-100. PubMed ID: 32216970
[No Abstract] [Full Text] [Related]
15. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
16. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
